Pharma Surge

Pharma Surge

🌍·Jul 15Industry

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Publisher

A
Allogene Therapeutics

Global

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Allogene Therapeutics
Region
Global
Scope
Industry
Published
July 15, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on ir.allogene.com

Leave the platform to read the original full article on the publisher site.

Source: Allogene Therapeutics

Scope: Industry

Open original article
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors | Pharma Surge